- Home
- SAIH vs CLRB Comparison
SAIH vs CLRB Comparison
Compare SAIH & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- CLRB
- Stock Information
- Founded
- SAIH 2019
- CLRB 2002
- Country
- SAIH Singapore
- CLRB United States
- Employees
- SAIH N/A
- CLRB N/A
- Industry
- SAIH
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- SAIH
- CLRB Health Care
- Exchange
- SAIH NYSE
- CLRB Nasdaq
- Market Cap
- SAIH 13.4M
- CLRB 12.5M
- IPO Year
- SAIH N/A
- CLRB N/A
- Fundamental
- Price
- SAIH $6.98
- CLRB $0.36
- Analyst Decision
- SAIH
- CLRB Hold
- Analyst Count
- SAIH 0
- CLRB 2
- Target Price
- SAIH N/A
- CLRB N/A
- AVG Volume (30 Days)
- SAIH 44.2K
- CLRB 34.3M
- Earning Date
- SAIH 04-28-2025
- CLRB 05-13-2025
- Dividend Yield
- SAIH N/A
- CLRB N/A
- EPS Growth
- SAIH N/A
- CLRB N/A
- EPS
- SAIH N/A
- CLRB N/A
- Revenue
- SAIH $5,543,000.00
- CLRB N/A
- Revenue This Year
- SAIH N/A
- CLRB N/A
- Revenue Next Year
- SAIH N/A
- CLRB N/A
- P/E Ratio
- SAIH N/A
- CLRB N/A
- Revenue Growth
- SAIH N/A
- CLRB N/A
- 52 Week Low
- SAIH $3.00
- CLRB $0.22
- 52 Week High
- SAIH $26.98
- CLRB $3.42
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- CLRB 61.13
- Support Level
- SAIH N/A
- CLRB $0.23
- Resistance Level
- SAIH N/A
- CLRB $0.69
- Average True Range (ATR)
- SAIH 0.00
- CLRB 0.05
- MACD
- SAIH 0.00
- CLRB 0.02
- Stochastic Oscillator
- SAIH 0.00
- CLRB 26.84
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations. The Company has four reportable segments: equipment sales, hosting, mining pool business, and mining.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.